The future holds promise for robots to actively collaborate in diverse aspects of human endeavor, transforming industries ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Australian researchers said that supervised diets with intermittent fasting were for children with serious health conditions, ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

Puravive is a weight loss supplement that has become a topic of discussion in the market over the last few weeks. This ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.

A new weight loss pill developed by the maker of Ozempic and Wegovy helped overweight and obese people lose up to 13% of ...